Reduction of pentagastrin stimulated acid output: a suitable method to predict efficacy of an irreversible proton pump inhibitor in peptic ulcer disease?
Bliesath
H
H
Byk Gulden Research Division, Konstanz, Germany.
Simon
B
B
Hartmann
M
M
Müller
P
P
Schneider
A
A
Lühmann
R
R
Wurst
W
W
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000284:Administration, Oral; D000328:Adult; D000897:Anti-Ulcer Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001562:Benzimidazoles / Q000627:therapeutic use; D004311:Double-Blind Method; D004381:Duodenal Ulcer / Q000188:drug therapy*; D005744:Gastric Acid / Q000378:metabolism*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D009853:Omeprazole / Q000031:analogs & derivatives; D000077402:Pantoprazole; D010418:Pentagastrin / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D054328:Proton Pump Inhibitors; D017494:Proton Pumps / Q000187:drug effects*; D016037:Single-Blind Method; D013454:Sulfoxides / Q000627:therapeutic use
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D054328:Proton Pump Inhibitors; D017494:Proton Pumps; D013454:Sulfoxides; D000077402:Pantoprazole; D010418:Pentagastrin; D009853:Omeprazole